HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer.

AbstractBACKGROUND AND OBJECTIVES:
To measure the fluence at tissue surface for patients in our Phase II clinical trial of motexafin lutetium (MLu)-mediated chest wall photodynamic therapy for recurrent breast carcinoma and to compare it to the calculated irradiance.
STUDY DESIGN/MATERIALS AND METHODS:
The spatial and time dependence of light fluence (rate) was monitored in vivo on the chest wall surface using isotropic detectors in five patients. Patients were given MLu either 4 mg/kg with light at 18 hours or 5 mg/kg with light at 24 hours using an irradiance of 150 J/cm(2) at 730 nm, with an incident fluence rate of 75 mW/cm(2). The ratio of fluence rate to the incident fluence rate was determined at the center of the treatment field. This ratio was used to estimate the effective attenuation coefficient, mu (eff).
RESULTS:
The mean and standard deviation of the ratio for all patients was 1.6 +/- 0.2. The corresponding range of mu (eff) was between 0.87 and 2.1 cm(-1), assuming reduced scattering coefficient, mu (s) = 4 cm(-1).
CONCLUSIONS:
A conversion factor was determined to convert the irradiance to fluence rate on the tissue surface. However, the fluence (or the ratio) on patient surface varied by 70% due to the heterogeneity of optical properties. This supports the use of real-time in vivo dosimetry during photodynamic therapy.
AuthorsAndreea Dimofte, Timothy C Zhu, Stephen M Hahn, Robert A Lustig
JournalLasers in surgery and medicine (Lasers Surg Med) Vol. 31 Issue 5 Pg. 305-12 ( 2002) ISSN: 0196-8092 [Print] United States
PMID12430147 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
CopyrightCopyright 2002 Wiley-Liss, Inc.
Chemical References
  • Metalloporphyrins
  • Photosensitizing Agents
  • motexafin lutetium
Topics
  • Adult
  • Breast (radiation effects)
  • Breast Neoplasms (drug therapy)
  • Female
  • Humans
  • Light
  • Metalloporphyrins (therapeutic use)
  • Neoplasm Recurrence, Local (drug therapy)
  • Photochemotherapy
  • Photosensitizing Agents (therapeutic use)
  • Radiometry
  • Reproducibility of Results
  • Scattering, Radiation
  • Thoracic Wall (radiation effects)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: